TOPIVERT
TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye. The lead GI programme TOP1288 is currently in a Phase IIa proof of concept study in ulcerative colitis. A Phase I/II study with TOP1630 for dry eye syndrome will commence in the US in early 2017.
TOPIVERT
Industry:
Angel Investment Biotechnology Health Care Management Information Systems
Founded:
2011-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.topivert.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
19.9 M USD
Technology used in webpage:
Google Analytics Google Universal Analytics GoDaddy DNS ASP.NET IIS Pound Sterling IIS 8 Parallels Plesk Panel Plesk Classic ASP
Current Advisors List
Current Employees Featured
Founder
Investors List
SV Health Investors
SV Health Investors investment in Series A - TopiVert
Neomed Management
Neomed Management investment in Venture Round - TopiVert
Imperial Innovations
Imperial Innovations investment in Venture Round - TopiVert
SV Health Investors
SV Health Investors investment in Venture Round - TopiVert
Johnson & Johnson Development Corporation
Johnson & Johnson Development Corporation investment in Venture Round - TopiVert
Imperial Innovations
Imperial Innovations investment in Venture Round - TopiVert
SV Health Investors
SV Health Investors investment in Venture Round - TopiVert
Official Site Inspections
http://www.topivert.com Semrush global rank: 5.39 M Semrush visits lastest month: 1.56 K
- Host name: ec2-13-216-111-180.compute-1.amazonaws.com
- IP address: 13.216.111.180
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
